1. Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy
Bleeding events impact negatively on prognosis in patients with acute coronary syndrome (ACS) whether they are undergoing percutaneous coronary intervention (PCI) or not1,2. Identifying high bleeding risk (HBR) patients has crucial implications for clinical and pharmacological management and for prognosis. Some trials assessing different stent platforms and dual antiplatelet therapy (DAPT) have been conducted or are ongoing in these delicate patients; however, the lack of standardisation in defining HBR patients inevitably limits trial design, data interpretation, and clinical decision making. The Academic Research Consortium for HBR (ARC-HBR) recently proposed criteria to standardise the definition of HBR for use in ...
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Read next articleThrombolysis in ST-elevation myocardial infarction is not dead